These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16469131)

  • 1. Do fluoroquinolones actually increase mortality in community-acquired pneumonia?
    Agarwal R
    Crit Care; 2006 Feb; 10(1):403; author reply 403. PubMed ID: 16469131
    [No Abstract]   [Full Text] [Related]  

  • 2. Community-acquired pneumonia.
    Luh JY; Karnath BM
    N Engl J Med; 2003 Apr; 348(14):1408-9; author reply 1408-9. PubMed ID: 12672875
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity.
    Singh A
    Clin Infect Dis; 2007 Jul; 45(1):133; author reply 134-5. PubMed ID: 17554716
    [No Abstract]   [Full Text] [Related]  

  • 4. Should fluoroquinolones be first-line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis?
    Hsueh PR
    J Microbiol Immunol Infect; 2007 Oct; 40(5):386-7. PubMed ID: 17932596
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral antibiotics prior to hospitalisation for community-acquired pneumonia.
    Charles PG
    Eur Respir J; 2008 Feb; 31(2):478-9; author reply 479. PubMed ID: 18238957
    [No Abstract]   [Full Text] [Related]  

  • 6. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story?
    Laterre PF
    Clin Infect Dis; 2008 May; 46(10):1510-2. PubMed ID: 18419483
    [No Abstract]   [Full Text] [Related]  

  • 7. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Schriger DL; Hoffman JR; Cooper RJ; Gupta M
    J Emerg Med; 2007 Aug; 33(2):197; discussion 197. PubMed ID: 17692777
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-acquired pneumonia guidelines: Peering back through the looking glass...clearly?
    Peterson MW; Hornick DB
    Am J Med; 2004 Nov; 117(10):799-800. PubMed ID: 15541330
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of different empirical antibiotic treatment regimens for community-acquired pneumonia on the emergence of Clostridium difficile.
    Bruns AH; Oosterheert JJ; Kuijper EJ; Lammers JW; Thijsen S; Troelstra A; Hoepelman AI
    J Antimicrob Chemother; 2010 Nov; 65(11):2464-71. PubMed ID: 20823105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-acquired pneumonia.
    Bartlett JG
    Int J Clin Pract Suppl; 2000 Dec; (115):18-22. PubMed ID: 11219294
    [No Abstract]   [Full Text] [Related]  

  • 12. Community-acquired pneumonia in elderly patients and length of hospitalization.
    Masotti L; Ceccarelli E; Cappelli R; Barabesi L; Forconi S
    Arch Intern Med; 2000 Sep; 160(17):2678-9. PubMed ID: 10999985
    [No Abstract]   [Full Text] [Related]  

  • 13. [Community acquired pneumonia: how to proceed when the antibiotic does not help?].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Sep; 153(38):12, 14. PubMed ID: 21977789
    [No Abstract]   [Full Text] [Related]  

  • 14. [Changes in guidelines for the therapy of non-nosocomial pneumonitis].
    Navazio F
    Clin Ter; 2000; 151(1):25-7. PubMed ID: 10822878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness.
    File TM; Tan JS
    Clin Infect Dis; 2005 Dec; 41(12):1706-8. PubMed ID: 16288391
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S
    J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113
    [No Abstract]   [Full Text] [Related]  

  • 17. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Halpern MT; Cifaldi MA
    Clin Infect Dis; 2004 Jul; 39(1):144-5; author reply 145-6. PubMed ID: 15206068
    [No Abstract]   [Full Text] [Related]  

  • 18. [Severe community-acquired pneumonia hospitalized--recent data confirm the interest of combined therapy].
    Fumeaux T
    Rev Med Suisse; 2014 Nov; 10(450):2172-3. PubMed ID: 25549383
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia.
    Nazarian DJ; Eddy OL; Lukens TW; Weingart SD; Decker WW
    Ann Emerg Med; 2009 Nov; 54(5):704-31. PubMed ID: 19853781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibiotherapy for acute CAP in adults].
    Denes E
    Med Mal Infect; 2006; 36(11-12):718-33. PubMed ID: 17092678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.